Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01536886 · ClinicalTrials.gov registry record · Phase 2
LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris
A Phase 2 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 376
- Enrollment target
NCT01536886: Completed Phase 2 study, sponsored by LEO Pharma.
NCT01536886 is a Phase 2 study that has completed, run by LEO Pharma. The registered enrollment target is 376 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (183% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01536886, a Phase 2 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 376 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether LEO 90100 and calcipotriol plus betamethasone are effective in the treatment of psoriasis vulgaris.
Primary Outcome
Assessment of disease severity (Plaque thickening, Scaling and Erythema) using a 5-point scale (Clear, Almost clear, Mild, Moderate, Severe), based on the condition of the disease at the time of evaluation.
Interventions
- DRUG LEO 90100
- DRUG Betamethasone plus calcipotriol
- DRUG Ointment vehicle
- DRUG LEO 90100 vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2012-05 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
What the finished NCT01536886 record still lists
NCT01536886 is an interventional study that assigns participants to a tested intervention. The registered 376 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (183% higher).
The record links to 0 conditions, and to 4 interventions - of which LEO 90100 is the first listed.
NCT01536886 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01536886 about?
NCT01536886 is a clinical study titled "LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris". The purpose of this study is to investigate whether LEO 90100 and calcipotriol plus betamethasone are effective in the treatment of psoriasis vulgaris.
What is the current status of trial NCT01536886?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 376 participants. The study started on 2012-05. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01536886?
The interventions under investigation include: LEO 90100 (DRUG), Betamethasone plus calcipotriol (DRUG), Ointment vehicle (DRUG), LEO 90100 vehicle (DRUG).
Who is sponsoring clinical trial NCT01536886?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01536886's enrollment target sits among peer trials
376 116th of 2000 higher than 1,885 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03102125 · 376 participants · Phase 4
Allograft Dysfunction in Heart Transplant
- NCT05055297 · 376 participants · NA
SELUTION4BTK Trial
- NCT05912647 · 376 participants · NA
Enhancing Diabetes Management Approaches for Patients With Uncontrolled Diabetes
- NCT05963971 · 376 participants · NA
A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia